Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU Authorization
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
Mirum Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections
Mirum Pharmaceuticals Analyst Ratings